Novo Nordisk A/S
Pagina dedicata companiei Novo Nordisk A/S listata cu simbolul US.NVO
Descriere companieModificare
Novo Nordisk A/S (https://www.novonordisk.com/) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Grafic actiuni companieModificare
Ultimele stiri despre Novo Nordisk A/S (US.NVO)Modificare
- Inflatia urca la 10.9% - 15 iunie 2026
- Preturile din industrie raman ridicate - 04 iunie 2026
- Euro urca la maxim istoric - 07 mai 2026
- BNR mentine dobanda cheie - 08 aprilie 2026
- Preturile industriale - scadere lunara, crestere anuala - 03 aprilie 2026
- Dinamica peste regiune - 02 aprilie 2026
- Dividende sub nivelul anului trecut - 01 aprilie 2026
- Buget strans pentru 2026 - 24 martie 2026
- Castigul sistemului bancar la nivel record - 03 martie 2026
- Recesiunea tehnica impune prudenta in 2026 - 24 februarie 2026